Author(s): Ramanjaneyulu K. V, Venkata Ramana K, M. Prasada Rao

Email(s): ram.ramanji@gmail.com

DOI: 10.5958/0974-360X.2020.00373.X   

Address: Ramanjaneyulu K. V1, Venkata Ramana K1,2, M. Prasada Rao3
1Department Pharmaceutical Analysis, Acharya Nagarjuna University, Guntur, Andhra Pradesh.
2Principal, A.S.N College of Pharmacy, Tenali, Guntur, Andhra Pradesh.
3Principal, M.A.M College of Pharmacy, Kesanupalli, Narasaraopet - 522601, Guntur, Andhra Pradesh.
*Corresponding Author

Published In:   Volume - 13,      Issue - 5,     Year - 2020


ABSTRACT:
Ivacaftor and Tezacaftor are the combined medication prescribed for the treatment of cystic fibrosis mutation. A simple and accurate stability indicating HPLC method was developed for separation and simultaneous analysis of Ivacaftor and Tezacaftor. The method utilizes a mobile phase composition of ammonium acetate buffer (pH 5.0) and acetonitrile in the ratio of 60:40 (v/v) as mobile phase at a flow rate of 1.0 mL/min and the separation of Ivacaftor and Tezacaftor was achieved on Sunfire C18 column (150mm×4.6mm; 3.5µ id) and the column eluents were recorded using UV detector at a wavelength of 260 nm. In these conditions, Ivacaftor and Tezacaftor elutes at a retention time of 1.8 min and 3.5 min respectively with a shortest run time of 5 min. The calibration curve was observed within the concentration range of 50-150 µg/mL for TZCF and 75-225 µg/mL IVCF with a correlation of more than 0.999 for both the drugs. The method was found to be precise, accurate and robust and is enough sensitive for the analysis of Ivacaftor and Tezacaftor. The forced degradation study confirms that Ivacaftor and Tezacaftor were found to be stable in the stress conditions and can effectively separate the degradation compounds. Hence the method can be suitably applicable for the routine analysis of Ivacaftor and Tezacaftor in formulation and stability studies.


Cite this article:
Ramanjaneyulu K. V, Venkata Ramana K, M. Prasada Rao. Stability indicating LC Method Development and Validation for the Simultaneous analysis of Cystic Fibrosis Drugs - Ivacaftor and Tezacaftor in Pharmaceutical Formulations. Research J. Pharm. and Tech 2020; 13(5): 2076-2080. doi: 10.5958/0974-360X.2020.00373.X

Cite(Electronic):
Ramanjaneyulu K. V, Venkata Ramana K, M. Prasada Rao. Stability indicating LC Method Development and Validation for the Simultaneous analysis of Cystic Fibrosis Drugs - Ivacaftor and Tezacaftor in Pharmaceutical Formulations. Research J. Pharm. and Tech 2020; 13(5): 2076-2080. doi: 10.5958/0974-360X.2020.00373.X   Available on: https://rjptonline.org/AbstractView.aspx?PID=2020-13-5-3


REFERENCES:
1.    Katherine RG, Obstetric Imaging: Fetal Diagnosis and Care (Second Edition). Elsevier - Academic Press, Massachusetts , USA. 2018; pp 579-581.
2.    William LE, Cystic Fibrosis, xPharm: The Comprehensive Pharmacology Reference. 2007; pp 1-5.
3.    FDA guidelines, SYMDEKO™ (tezacaftor/ivacaftor; ivacaftor) Tablets, Reference ID: 4220295, 2018; 1-15(https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210491lbl.pdf)
4.    Jennifer Taylor Cousar, Minoo Niknian and Geoffrey Gilmartin et al. Effect of ivacaftor in patients with advanced cystic fibrosis and a G551D-CFTR mutation: Safety and efficacy in an expanded access program in the United States. Journal of Cystic Fibrosis.2016; 15(1): 116-122.
5.    Gadeela Srimounika, Shyamala and Sharma JVC et al. A new stability- indicating method for simultaneous estimation of ivacaftor and tezacaftor by RP-HPLC in bulk and its dosage form. IJRAR. 2018; 5(4): 774-785.
6.    Kiranjyothi R, Balakrishnan M and Chandrasekhar KB. Method development and validation for the stability indicating simultaneous estimation of tezacaftor and ivacaftor in bulk and its dosage forms. International Journal of Pharmaceutical Research. 2018; 10(4):
7.    Janardhana Reddy VL, Raveendrareddy P and Sreenivasulu. Method development and validation of Ivacaftor in bulk and pharmaceutical dosage form by UV spectrophotometer, Int. J.Res.Pharm.Sci. 2018; 9(40): 1169-1173.
8.    Gautam CHVS, Saicharan K and Swathi B. Method Development and Validation of Ivacaftor in Bulk & Pharmaceutical Dosage Form by Uv-Visible Spectrophotometry. IAJPS. 2019; 06 (04): 7476-7481.
9.    Akram NMD and Umamahesh M. A New Validated RP-HPLC Method for the Determination of Lumacaftor and Ivacaftor in its Bulk and Pharmaceutical Dosage Forms. Orient. J. Chem. 2017; 33(3): 1492-1501.
10.    Pasala Sandhya Mounika and Rameeja Pattan. Stability Indicating RP-HPLC Method for Simultaneous Estimation of Lumacaftor and Ivacaftor in Bulk and Pharmaceutical Dosage Forms. Pharma research Library. 2019; 7(1):
11.    Suresh Babu M, Spandhana N and Baby Rani P et al. Analytical method development and validation for the estimation of Lumacaftor and Ivacaftor using RP-HPLC. Journal of Pharmacreations. 2017; 4(1): 55-78.
12.    Nagamallika Gorantla, Jyothi Dodlapati and Sujatha Jadi. A New Validated RP-HPLC Method for Simultaneous Estimation of Lumacaftor and Ivacaftor in Pharmaceutical Dosage Form. Int. J. Pharm. Sci. Rev. Res. 2019; 56(1): 30-37.
13.    Sravanthi B, Divya M. Analytical Method Development and Validation of Ivacaftor and Lumacaftorby RP-HPLC Method. IAJPS. 2016; 3(8): 900-904.
14.    Baki Sharon, Meruva Sathish Kumar and Marakatham S et al. A New RP-UPLC Method Development and Validation forthe Simultaneous Estimation of Ivacaftor and Lumacaftor. J. Global Trends Pharm Sci. 2018; 9(3): 5730- 5737.
15.    Elena K Schneidera, Felisa Reyes-Ortegaa and John W. Wilson et al. Development of HPLC and LC–MS/MS methods for the analysis of ivacaftor, its major metabolites and lumacaftor in plasma and sputum of cystic fibrosis patients treated with Orkambi or Kalydeco. Journal of Chromatography B. 2016; 1038:  57–62.
16.    Elena K, Schneider and Felisa Reyes-Ortega et al. Development of HPLC and LC-MS/MS methods for the analysis of ivacaftor, its major metabolites and lumacaftor in plasma and sputum of cystic fibrosis patients treated with Orkambi Or Kalydeco, J Chromatogr B AnalytTechnol Biomed Life Sci. 2016; 1038: 57–62.
17.    Mohan Goud V, Sharma JVC and Sravanthi M. Stability Indicating Ultra Performance Liquid Chromatography Method Development And Validation For Simultaneous Estimation Of Ivacaftor and Tezacaftor In Bulk And Pharmaceutical Dosage Form. International Journal of Scientific Research and Review. 2019; 8(5); 129-133.
18.    Bikshal B.K., Useni R.M., Venkateswara R.A., and Maheshwara R.L., Intended high-performance liquid chromatography procedure for the quantification of norfloxacin and its potential impurities in active pharmaceutical ingredient and tablet dosage forms, Thai Journal of Pharmaceutical Sciences, 2018; 42(1): 27-36.
19.    ICH Validation of Analytical Procedures: Text and Methodology Q2 (R1), 4, 1994; 1-13.

Recomonded Articles:

Research Journal of Pharmacy and Technology (RJPT) is an international, peer-reviewed, multidisciplinary journal.... Read more >>>

RNI: CHHENG00387/33/1/2008-TC                     
DOI: 10.5958/0974-360X 

0.38
2018CiteScore
 
56th percentile
Powered by  Scopus


SCImago Journal & Country Rank


Recent Articles




Tags


Not Available